Cruchaga et al. 1 recently showed that: (1) variants in the phospholipase D3 (PLD3) gene confer increased risk for the development of Alzheimer's disease (AD); (2) PLD3 expression is decreased in patients with sporadic Alzheimer's disease; and (3) the expression of PLD3 inversely correlates with the expression of amyloid precursor protein (APP) and the production of amyloid-β peptides in vitro in cell lines. Altogether, the genetic and functional data led the authors to conclude that PLD3 loss-of-function confers an increased Alzheimer's disease risk by affecting APP processing. We tested the relevance of PLD3 for APP processing in vivo in physiological conditions and in a relevant Alzheimer's disease mouse model and found that PLD3 deficiency did not affect APP metabolism or amyloid plaque burden. However, PLD3 is localized in the lysosomal compartment and its loss-of-function alters lysosomal morphology, suggesting alternative functions for PLD3 in neurodegeneration.
To test the effect of loss-of-function of PLD3 on brain physiology we acquired the Pld3
. These mice carry a trapping cassette with a splicing acceptor followed by a IRES:lacZ knocked-in in the Pld3 gene (Extended Data Fig. 1a ). This insertion abrogates the expression of Pld3 and results in the expression of the β -galactosidase reporter instead (Extended Data Fig. 1b) . Western blotting analysis (not shown) and X-gal staining showed that PLD3 is highly expressed in the pyramidal neurons of the cortex and hippocampus; conversely, the expression of the β -galactosidase was not detectable in the interneurons of the hippocampus nor in the glial cells of the corpus callosum (Extended Data Fig. 1d ). Morphometric analysis of the gross morphology of Pld3-deficient brains did not reveal any major abnormalities as compared to controls (Extended Data Fig. 1e, f) .
We investigated the effect of genetic deletion of Pld3 on APP proteolysis. mRNA levels of App and different candidate genes, including Adam10, Bace1 and the γ -secretase complex subunits, are unchanged in Pld3-deficient cortices relative to control brains (Extended Data  Fig. 1c) . Moreover, western blotting analysis shows that the expression of full-length APP, C-terminal APP fragments, and the ratio between full-length and C-terminal fragments are not affected by Pld3 deletion in either the cortex or the hippocampus (Fig. 1a, b and Extended Data Fig. 1g, h ). We also assessed the levels of Aβ 40 and Aβ 42 in control and Pld3-deficient mice by performing enzyme-linked immunosorbent assays (ELISAs). Notably, genetic deletion of Pld3 does not affect endogenous Aβ 40 and Aβ 42 generation in the cortex and hippocampus of 3-month-old adult mice (Fig. 1b and Extended Data Fig. 1h ).
To establish the relevance of PLD3 in a mouse model of Alzheimer's disease, we crossed Pld3 ko mice with App knock-in mice (App ki ) that have a humanized amyloid-β sequence in the endogenous App gene and contain three clinical relevant mutations to increase amyloidogenesis 3 . The model proposed by Cruchaga et al. 1 predicts that the loss of Pld3 function would increase amyloid-β burden. Consistent with the experiments above, Pld3 deletion did not alter the levels of full-length APP, C-terminal APP fragments, or the ratio of the two (Fig. 1c, d ). The levels of Aβ 40 and Aβ 42 in TBS-soluble and guanidine-HCl-soluble fractions were not increased in Pld3 ko ; App ki mice compared to controls ( Fig. 1d and Extended Data Fig. 1i ). Most importantly, Pld3 deletion did not have any effect on the burden of amyloid-β plaques (Fig. 2a, b) , providing further confirmation that PLD3 does not affect APP metabolism in this Alzheimer's disease mouse model. Future studies will be required to investigate the effect of PLD3 deletion in aged mice or in other Alzheimer's disease models (such as tau or ApoE models).
We then tried to replicate the in vitro studies of Cruchaga et al. 1 using transiently expressed wild-type PLD3, the catalytically inactive PLD3(K418R) variant 4 and the Alzheimer's disease-linked PLD3(V232M) variant in HEK293T cells stably expressing wild-type human APP. The results of these experiments were contradictory and highly variable. Consistent with Cruchaga et al. 1 , we observed a reduction in amyloid-β levels in cells expressing the wild-type and mutant PLD3 proteins (Extended Data Fig. 2a) . In contrast to Cruchaga et al. 1 , full-length APP fragments were not significantly affected by PLD3 expression (Extended Data Fig. 2b, c) . Unexpectedly, the expression of the PLD3(V232M) variant, proposed as a loss-of-function allele by Cruchaga et al. 1 , also decreased amyloid-β generation. Notably, the overexpression of PLD3 in these experiments was more than 50-fold higher than the endogenous expression (not shown). We reasoned that the discrepancies in the results are probably explained by overexpression artefacts; for example, huge overexpression may lead to mislocalization of the protein of interest, resulting in non-physiological interactions. Therefore, we further investigated the functional relevance of changes in PLD3 expression by using milder overexpression conditions to mimic a physiologically relevant context more closely. We expressed decreasing amounts of wild-type PLD3 and the PLD3(K418R) and PLD3(V232M) mutants by neon electroporation in HEK293T cells to allow for a more uniform expression of the PLD3 . In this experimental model, the expression of wild-type or mutant PLD3 does not reduce either amyloid-β levels (Extended Data Fig. 2d ) or APP expression (Extended Data Fig. 2e, f) , confirming that the reported effects of PLD3 on APP reported in Cruchaga et al. 1 are artefacts owing to huge overexpression of PLD3.
Several Alzheimer's disease-linked genes, that do not directly control APP processing, converge on the regulation of endosomalautophagic-lysosomal function 5 , although the aetiological role of endosomal-lysosomal impairment in Alzheimer's disease is not completely understood 6, 7 . Notably, defects in the endosomal-lysosomal system were found in the brains of patients with Alzheimer's disease 8 . Thus, we investigated the localization of PLD3 in early endosomes (stained with the early endosome antigen 1 (EEA1) marker) and in late endosomes and lysosomes (visualized with the lysosomal-associated membrane protein 1 (LAMP1) marker). PLD3 was not enriched in early endosomes but was mostly localized to LAMP1-positive compartments (Extended Data Fig. 3a-d) . Hence, we analysed by electron microscopy the ultrastucture of lysosomes in Pld3 ko neurons. Primary and secondary lysosomes of Pld3-deficient CA1 neurons displayed an increase in density, size and in total area occupied (Extended Data Fig. 3e-g ). Moreover, several of these secondary lysosomes showed electron-transparent inclusions compatible with lipid droplets (16 out of 73 secondary lysosomes in Pld3 ko mice brains versus 1 out of 22 in controls). The precise mechanisms underpinning these alterations is not clear, although these results show that PLD3 is required to preserve the structure of lysosomes in vivo.
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